Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies

“… 14 The GIM2 study was a multicentre, randomized phase III trial with a 2 × 2 factorial design comparing the efficacy and safety of adjuvant anthracycline- and taxane-based chemotherapy with or without the inclusion of fluorouracil administered with a dose-dense schedule or a standard-interval schedule in node-positive breast cancer patients. 15 In both trials, patients with hormone-receptor-positive tumours received adjuvant endocrine therapy following cytotoxic treatment completion. 14 , 15 The GIM3 study was a multicentre, randomized phase III trial with a 2 × 3 factorial design comparing the three aromatase inhibitors (letrozole vs. anastrozole vs. exemestane) and the upfront vs. switch (after 2 years of tamoxifen) treatment strategy in postmenopausal women with hormone receptor-positive early breast cancer.…”

“… 15 In both trials, patients with hormone-receptor-positive tumours received adjuvant endocrine therapy following cytotoxic treatment completion. 14 , 15 The GIM3 study was a multicentre, randomized phase III trial with a 2 × 3 factorial design comparing the three aromatase inhibitors (letrozole vs. anastrozole vs. exemestane) and the upfront vs. switch (after 2 years of tamoxifen) treatment strategy in postmenopausal women with hormone receptor-positive early breast cancer. 16 The GIM4 study was a multicentre, open-label, randomized, phase III trial comparing extended adjuvant endocrine therapy with letrozole for an additional 5 years vs. 2–3 years in postmenopausal breast cancer patients previously exposed to 3-2 years of tamoxifen.…”

Hormone Receptor-Positive / HER2-Negative Early Breast Cancer High-Risk Population: An Algorithm for Optimization Systemic Adjuvant Treatment Based on 2022 Updates

“…Similarly, fluorouracil demonstrated that it does not add benefit in DFS, reason why it should be avoided in the anthracyclines scheme. 32 Frail and older patients (⩾ 70 years) are special populations to tailored-adjuvant treatment. HOPE study showed that the use of anthracycline-based, alkylating, and taxane-based regimens had a three times higher relative dose intensity index ⩽ 85%, resulting in a 11% decrease in 5-year survival.…”

Factors related to oral mucositis or dysgeusia in breast cancer patients undergoing fluorouracil, epirubicin, and cyclophosphamide therapy: A single-center, retrospective study

“…However, despite these efforts, there are currently no established preventive measures for OM or dysgeusia. Thus, this retrospective study aimed to identify factors for the development of OM or dysgeusia in breast cancer patients treated with 5-uorouracil 500 mg/m², epirubicin 100 mg/m², and cyclophosphamide 500 mg/m² (FEC) every 3 weeks for four cycles [17][18][19]. The ultimate goal was to facilitate the development of targeted strategies aimed at improving the QoL of patients undergoing chemotherapy.…”